RNTX

Rein Therapeutics Inc

0.5821

Oct 23 • 3:59 PM ET -0.0203 (-3.37%)

0.5821

Aftermarket • 4:15 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: PLRX VCRE AVLN TVRD GYRE SKYE SVRA GALT PULM IVA

| Held by: VTI VXF IWC ONEQ

Scroll to Statements

Index	-
Market Cap	50.22M
Enterprise Value	54.58M
Income	-49.76M
Sales	0.00M
Book/sh	0.12
Cash/sh	0.47
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Jun 29, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.89
P/C	1.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.27
Current Ratio	4.27
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.72
EPS next Y	-0.47
EPS next Q	-0.10
EPS this Y	76.53%
EPS next Y	-1.09%
EPS next 5Y	32.79%
EPS past 3/5Y	31.21% 30.56%
Sales past 3/5Y	- -
EPS Y/Y TTM	36.23%
Sales Y/Y TTM	-
EPS Q/Q	66.32%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	41.18% -

Insider Own	8.49%
Insider Trans	0.99%
Inst Own	48.73%
Inst Trans	49.50%
ROA	-80.62%
ROE	-96.42%
ROIC	-90.14%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-18.42%
SMA50	-23.29%
SMA200	-44.60%
Trades

Shs Outstand	85.77M
Shs Float	78.95M
Short Float	0.82%
Short Ratio	1.45
Short Interest	0.65M
52W High	2.18 -73.30%
52W Low	0.54 7.78%
Volatility	9.06% 10.60%
ATR (14)	0.07
RSI (14)	36.71
Beta	1.47
Rel Volume	0.74
Avg Volume	448.07K
Volume	331,334

Perf Week	-1.39%
Perf Month	-21.76%
Perf Quarter	-25.52%
Perf Half Y	-64.93%
Perf YTD	-49.82%
Perf Year	-53.80%
Perf 3Y	-53.80%
Perf 5Y	-96.97%
Perf 10Y	-
Recom	1.00
Target Price	6.00
Prev Close	0.60
Price	0.58
Change %	-3.37%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-22-25	Initiated	H.C. Wainwright	Buy	$10
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$8
Jul-24-17	Initiated	William Blair	Outperform
Jul-24-17	Initiated	Jefferies	Buy	$20
Jul-24-17	Initiated	BofA/Merrill	Buy	$19

Sep-04-26 08:00AM	Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress (GlobeNewswire) +5.39%
Sep-03-26 04:01PM	Rein Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) +8.88%
Aug-20-26 08:00AM	Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Aug-14-26 06:44AM	Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-26 08:00AM	Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications (GlobeNewswire)
08:00AM	Loading…
Jul-21-26 08:00AM	Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries (GlobeNewswire) +6.02%
Jun-11-26 08:00AM	Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom (GlobeNewswire)
May-18-26 08:00AM	Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
Apr-30-26 08:00PM	Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +6.27% -23.99%
Apr-29-26 08:00AM	Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis (GlobeNewswire) -12.07%
Mar-03-26 08:00AM	Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jan-20-26 08:00AM	Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Nov-06-25 07:30AM	Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF (GlobeNewswire)
Nov-03-25 07:30AM	Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (GlobeNewswire) +11.82%
Oct-09-25 07:30AM	Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
07:30AM	Loading…
Sep-17-25 07:30AM	Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Aug-19-25 09:32AM	Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Aug-14-25 05:00PM	Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 (GlobeNewswire)
Jul-30-25 08:30AM	Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing (GlobeNewswire)
Jun-24-25 10:11AM	Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders (PR Newswire)
May-27-25 07:00AM	Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF (PR Newswire)
May-19-25 04:51PM	Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference (PR Newswire) -10.23%
May-15-25 04:09PM	Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -6.36%
May-12-25 07:00AM	Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF (PR Newswire)
May-01-25 07:00AM	Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF (PR Newswire)
Apr-30-25 04:05PM	Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 (PR Newswire)
Apr-28-25 07:00AM	Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference (PR Newswire) -7.85%
Apr-23-25 07:00AM	Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases (PR Newswire)
Apr-15-25 07:00AM	Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F (PR Newswire)
04:17PM	Loading…
Apr-07-25 04:17PM	Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (PR Newswire) -15.24%
Jan-10-25 11:30AM	Aileron Therapeutics Announces Rebranding to Rein Therapeutics (PR Newswire) +9.33%
Nov-14-24 04:15PM	Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire) -7.28% -13.29%
Nov-13-24 01:04PM	Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis (Benzinga) -6.79%
07:00AM	Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) (PR Newswire)
Oct-31-24 07:30AM	Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma (PR Newswire) +7.01%
Oct-12-24 09:00AM	Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis (PR Newswire)
Sep-23-24 07:30AM	Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) (PR Newswire)
Aug-19-24 04:05PM	Aileron Therapeutics to Present at the 8th Annual IPF Summit (PR Newswire) +13.76% +11.63%
Aug-14-24 06:05PM	Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (PR Newswire) -10.19% -10.81%
Jul-30-24 08:00AM	Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
Jul-01-24 08:00AM	Aileron Therapeutics to be Included in the Russell Microcap Index (PR Newswire)
May-15-24 10:53PM	ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024 (InvestorPlace)
05:13PM	Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-07-24 09:35AM	Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround (Zacks) -6.58%
May-06-24 04:05PM	Aileron Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +5.05%
May-03-24 04:33PM	Aileron Therapeutics Closes Direct Offering of Shares, Warrants (MT Newswires)
04:05PM	Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million (GlobeNewswire)
May-02-24 07:24AM	Aileron reports data from cohort one of Phase Ib inhaled IPF treatment trial (Clinical Trials Arena) -8.17%
May-01-24 08:45AM	Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million (GlobeNewswire) -8.57%
08:30AM	Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire)
Apr-16-24 09:52AM	ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023 (InvestorPlace) -9.78%
Apr-15-24 05:20PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Aileron Therapeutics Announces CEO Transition (GlobeNewswire) -5.41%
Feb-15-24 04:05PM	Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event (GlobeNewswire)
Feb-01-24 04:30PM	Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 (GlobeNewswire) -6.06% +13.44%
Oct-31-23 12:30PM	Aileron Therapeutics Announces Acquisition of Lung Therapeutics (PR Newswire)
Apr-04-23 09:55AM	Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now (Zacks)
Mar-14-23 09:55AM	Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +12.12%
Feb-22-23 11:49AM	Cancer drugmaker down to 3 employees after trial failure (American City Business Journals) +6.16%
Feb-21-23 02:50PM	Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall (Benzinga) -37.77%
08:30AM	Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives (GlobeNewswire)
Dec-29-22 12:00PM	What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock (Zacks)
Nov-30-22 07:00AM	Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Nov-24-22 09:55AM	Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-10-22 08:00AM	Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split (GlobeNewswire) -11.98%
Nov-04-22 12:00PM	Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade (Zacks) +10.94%
Nov-01-22 08:15AM	Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Oct-26-22 06:05AM	Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference (GlobeNewswire) -5.83%
Sep-30-22 08:41AM	Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 (GlobeNewswire) -8.13%
Sep-22-22 08:00AM	Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire)
Sep-06-22 07:00AM	Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-15-22 04:15PM	Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Aug-01-22 07:51AM	Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer (GlobeNewswire) -15.68%
Jul-08-22 08:31AM	Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 (GlobeNewswire)
Jun-29-22 09:46AM	Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting (Benzinga) -27.14%
06:30AM	Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer (GlobeNewswire)
May-19-22 07:00AM	Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer (GlobeNewswire)
06:40AM	3 Oversold Biotech Stocks to Buy Now (InvestorPlace)
May-17-22 07:00AM	Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +12.92%
May-13-22 07:00AM	Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 (GlobeNewswire) +9.15%
May-11-22 07:57AM	Will Aileron Therapeutics (NASDAQ:ALRN) Spend Its Cash Wisely? (Simply Wall St.)
May-10-22 12:43PM	Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting (GlobeNewswire)
May-05-22 04:15PM	Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Apr-21-22 09:40AM	Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year? (Zacks) -6.12%
08:00AM	Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations (GlobeNewswire)
Apr-05-22 09:40AM	Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year? (Zacks) +5.88%
Mar-28-22 04:20PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire) -7.41%
Mar-22-22 08:04AM	Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Jan-27-22 01:38PM	Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ... (GuruFocus.com) -9.48%
Jan-05-22 08:04AM	Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones (GlobeNewswire) -7.27%
Jan-04-22 08:45AM	Aileron Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
07:00AM	CEO Presenting on the Emerging Growth Conference on January 5 Register Now (GlobeNewswire)
Dec-30-21 04:32AM	As Aileron Therapeutics, Inc.'s market cap (NASDAQ:ALRN) drops to US$47m, insiders might be questioning their decision to buy earlier this year (Simply Wall St.)
Dec-20-21 10:56AM	Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs (GlobeNewswire)
Nov-12-21 07:50AM	Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights (GlobeNewswire) -6.13%
Oct-07-21 09:22AM	Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity (GlobeNewswire)
Sep-30-21 04:30PM	Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 (GlobeNewswire)
Sep-16-21 02:33PM	Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent (Benzinga) -6.09%
08:15AM	Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924s Best-in-Class Potential as a Chemoprotective Agent (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VON RICKENBACH JOSEF H	Director	May 26 '26	Buy	1.06	23,190	24,470	58,014	May 28 08:15 PM
VON RICKENBACH JOSEF H	Director	May 22 '26	Buy	1.05	15,950	16,708	34,824	May 28 08:15 PM
VON RICKENBACH JOSEF H	Director	May 27 '26	Buy	1.07	4,500	4,819	62,514	May 28 08:15 PM
VON RICKENBACH JOSEF H	Director	May 21 '26	Buy	1.04	3,420	3,564	18,874	May 28 08:15 PM
WINDSOR JAMES BRIAN	See Remarks	Apr 30 '26	Buy	1.00	25,000	25,000	27,046	May 13 08:47 AM
Voss Capital, LP	10% Owner	Nov 14 '25	Buy	1.22	104,183	127,593	926,441	Nov 18 05:30 PM
Voss Capital, LP	10% Owner	Oct 28 '25	Buy	1.39	178,392	247,965	500,000	Oct 28 06:45 PM
Voss Capital, LP	10% Owner	Oct 27 '25	Buy	1.37	97,482	133,544	822,258	Oct 28 06:45 PM

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

CEODr. James Brian Windsor Ph.D.

M.B.A.Mr. Timothy M. Cunningham CPA

Chief Scientific OfficerDr. Cory M. Hogaboam Ph.D.

CounselMs. Jennifer Faigle

VP of Finance and Corporate ControllerMr. Ron Chen

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNTX

Rein Therapeutics Inc

Upgrade your Finviz experience